ROUTINE · canceR agnOstic immUnoTherapy predIctioN blood-tEst

Cancer is the second leading cause of death worldwide, accounting for 10M deaths in 2020. Although 7 Immune Checkpoint Inhibitors (ICI) are approved for different cancer indications and have represented a true breakthrough, only 10-50% of advanced cancer patients respond to the treatment. This unpredictability of results, together with 15-60% severe toxicity rates and high prices are restricting the impact potential of ICIs. Predicting ICI response is critical for fully realizing their potential in treating early-stage tumours and enhancing ICI treatment regimens.PamGenes IOpener is a ground-breaking in vitro diagnostics testing platform for ICI response prediction. Made possible by PamGenes proprietary microarray-based kinase activity profiling of host immune cells, it can predict a patients response before ICI therapy is started from a simple blood draw. The IOpener aims to revolutionize the precision-medicine sector, enabling the widespread use of ICIs at any cancer stage.